Lilly's halts trials of Zyprexa replacement in schizophrenia
This article was originally published in Scrip
Executive Summary
Eli Lilly ceded defeat in its fight to replace some of the revenue lost to generic competition for its blockbuster Zyprexa (olanzapine) when on 29 August it announced it would end development of the schizophrenia drug candidate pomaglumetad methionil (LY2140023) – an oral glutamate 2 and 3 receptor agonist – after a second pivotal study failure.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.